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Abstract 
The recently reported phenomenon that red blood cells (RBC) from Alzheimer disease (AD) patients and normal individuals, which 
have identical electrophoretic mobilities (EPM) in phosphate-buffered saline (PBS), have different EPM in appropriately selected polymer 
solutions, has been further explored. Of a number of in vitro treatments to which AD and normal RBC were subjected prior to EPM 
measurements in bottom phase (from a dextran-poly(ethylene glycol) (PEG) aqueous phase system) only trypsin eliminated the difference. 
Thus, the differential polymer interaction between AD and normal RBC, thought o be the basis for their dissimilar EPM, can be 
abolished by appropriate proteolytic modification of the cell surfaces and suggests protein as a source of difference. Because young and 
old RBC from normal individuals, which have the same EPM in PBS, have different EPM in certain polymer solutions, and the RBC 
from AD patients have been reported to age abnormally, we also compared the young and old RBC subpopulations from these two 
sources. By the criterion of cell electrophoresis in polymer solutions the differences between AD and normal RBC and between young 
and old RBC are distinct. The EPM of AD and normal RBC differ in bottom phase or PEG but not in dextran solution; while the EPM of 
young and old RBC differ predominantly in dextran. We speculate that since the observed ifference in EPM of RBC from AD patients 
and normals depends on protein(s) yet is anticoagulant-related (being obtained only when blood is collected in citrate or oxalate) it might 
be the result of an interaction (CaZ+-mediated?) between the surfaces of these cells and protein component(s) of their respective, 
compositionally differing sera. 
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1. Introduction 
Extra-neuronal abnormalities in Alzheimer disease 
(AD), including altered red blood cell (RBC) membranes 
[1] and aging patterns [2,3], have been the subject of many 
reports (see [4] for a review). These findings prompted us 
initially to examine whether such changes are reflected at 
the surface of RBC from AD patients by comparing these 
cells' partitioning and electrophoretic behavior to those of 
RBC from subjects without memory impairment or demen- 
tia ('normals'). Neither cell partitioning in a charge-sensi- 
tive dextran-poly(ethylene glycol) (PEG) aqueous phase 
system (i.e., one with a Donnan potential between the 
phases, top phase positive [5,6]) nor cell electrophoresis in 
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phosphate-buffered saline (PBS) revealed any difference 
between these cell populations. 
Recently we related the fortuitous circumstances that 
led us to examine the electrophoretic mobilities (EPM) of 
RBC from AD patients and from normals in a number of 
polymer solutions. We discovered significant differences 
in EPM between these RBC populations in some polymer 
solutions (i.e., bottom phase from a dextran-PEG phase 
systems; PEG solution in PBS) but not in others (i.e., top 
phase; dextran solution in PBS) [7]. RBC from AD patients 
have a higher mobility in the indicated polymer solutions 
than do RBC from normals. The altered EPM associated 
with RBC from AD patients was not found with RBC from 
patients with Parkinson's disease and the alteration is, 
therefore, not a phenomenon shared by RBC in all neuro- 
logic diseases [7]. 
Young and old RBC from normal individuals, which 
have identical EPM in PBS [8], have also been found to 
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have unequal EPM in polymer solutions, young RBC < old 
RBC [9,10]. Here EPM differences are readily apparent in 
dextran solution [9] and also, but on a percentage basis to a 
much smaller extent, in PEG solution, and in top and 
bottom phases [10]. These cells' behavior suggests thereby 
the involvement of surface properties other than or in 
addition to those permitting differentiation of RBC from 
AD patients and normals (see above). 
Studies on RBC from different species have shown that 
partitioning in a charge-sensitive dextran-PEG aqueous 
phase system and electrcphoresis in PBS or in selected 
polymer solutions (e.g., dextran-rich bottom phase; PEG- 
rich top phase) detect s~Jrface charge or charge-related 
properties [11]. At the same time each of these physical 
measures represents a distinct probe capable of reflecting 
different and cell populatJion-specific surface properties, a 
phenomenon ascribed to differences in the nature of poly- 
mer-specific nteraction with cell surfaces [11]. 
In the present work we have (a) determined that protein 
is responsible for the EPM differences between RBC from 
AD patients and normals, (b) studied the cell- and suspend- 
ing medium-specific effects on the EPM differences be- 
tween RBC from AD patients and normals and also be- 
tween young and old RBC in each of these cell popula- 
tions, and (c) examined the effect of a number of anticoag- 
ulants on the relative EPM of RBC from AD patients and 
normals. 
2. Materials and methods 
2.1. Reagents 
Dextran T500 (lot No. 01 06905) was obtained from 
Pharmacia LKB (Piscataway, NJ). PEG 8000 (Carbowax 
8000) was from Union Ca3~bide (Long Beach, CA). Trypsin, 
chymotrypsin and paraformaldehyde w re from Sigma (St. 
Louis, MO). All salts and organic solvents used were of 
analytical reagent grade. 
phy (SPECT). Subjects had been followed longitudinally 
for a minimum of 6 months (maximum 9 years) in a 
specialized program designed to establish progression of 
dementia nd to clarify the role of any identified concomi- 
tant medical disorders. Blood in these experiments was not 
obtained during acute medical illness. Confirmation of 
clinical diagnoses of Probable AD post mortem from the 
clinical program (not including any members of the sample 
reported here) has been 100% to date (unpublished ata). 
Blood from AD patients and from normals, comprising 
some spouses of Alzheimer patients, some other elderly 
individuals and some younger donors who were employees 
of the VAMC and spanning the age range from 22 to 83 
years, was collected. When young and old red blood cells 
were to be prepared, the blood was processed (see below) 
within 1 h of collection. RBC were used within one week 
in all other experiments. For comparative purposes, in one 
set of experiments (where indicated), blood was collected 
in oxalate, heparin or EDTA vacutainers or was defibri- 
nated by gently swirling 10 ml of blood with 4 glass beads 
in a 50 ml Erlenmeyer flask for 10 min. 
2.3. Preparation of two-polymer aqueous phase systems 
and other standard solutions used 
Aqueous two-phase systems having the dextran and 
PEG concentrations and salt compositions and concentra- 
tions indicated in the tables or text were prepared as 
previously described [5,6]. PBS contained 0.15 M NaCI, 
0.01 M sodium phosphate buffer, pH 6.8. Solutions con- 
taining 4, 8 or 12% (w/w) dextran in PBS or 1, 2, 3, 5, 6, 
8% (w/w) PEG in PBS were prepared by weighing out 
the appropriate amounts of concentrated respective stock 
solutions [5,6] (i.e., of 20% (w/w) dextran, 40% (w/w) 
PEG, 0.44 M sodium phosphate buffer, pH 6.8, 0.60 M 
NaC1). 
2.4. Preparation of young and old red blood cell popula- 
tions from normal and Alzheimer patients' blood 
2.2. Collection of blood from normal individuals and 
Alzheimer patients 
Blood obtained by venipuncture from normal individu- 
als and from AD patients was collected in citrate vacutain- 
ers. As previously described in detail [7] all patients met 
criteria for Dementia [12] and for Probable or Possible AD 
[13]. Consent was obtained from patients and respective 
responsible parties per institutional guidelines and ap- 
proved procedures. Patients were selected after thorough 
evaluation including physical and mental status examina- 
tion, blood studies, electrocardiography, electroen- 
cephalography (EEG), a~Ld brain imaging with X-ray CT 
scan or magnetic resonance imaging of the brain [7]. The 
majority also had functional imaging with quantitative 
EEG and/or Single Photon Emission Computed Tomogra- 
Young and old RBC were separated by the centrifuga- 
tion method of Murphy [14] using approx. 2 ml of packed 
RBC per 10.7 × 77 mm centrifuge tube. About 7% of the 
upper and lower centrifuged blood cell layers were col- 
lected to obtain RBC populations enriched with respect o 
young (top layer) or old (bottom layer) cells as previously 
established [8,15]. The cells were washed three times in 
PBS and used in electrophoresis experiments ( ee below). 
2.5. In vitro treatments of red blood cells from normal 
individuals and Alzheimer patients 
Chymotrypsin and trypsin treatment [10] 
1 ml of packed RBC were washed three times with 10 
volumes of PBS, pH 7.4. 0.1 ml of washed RBC diluted in 
1 ml of PBS were incubated together with 50 /zg of either 
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trypsin (1 mg/ml  saline) or chymotrypsin at 37°C for 60 
rain. Controls were incubated in the absence of enzyme. 
The cells were washed three times with PBS and used in 
electrophoresis experiments. 
Formaldehyde fixation of red blood cells [10] 
RBC (from blood collected in citrate vacutainers) were 
washed three times with 10 volumes of PBS, pH 6.8. 1% 
paraformaldehyde in PBS was heated at about 80 ° C for 30 
min to obtain dissolution and the solution was then al- 
lowed to cool. 2 ml of washed packed RBC were added 
with continuous wirling to 18 ml of the formaldehyde 
solution. The mixture was permitted to remain at room 
temperature overnight. The clear formaldehyde solution 
was poured off and replaced with an equal volume of fresh 
1% formaldehyde solution. The cells were resuspended 
and stored in the cold (4-5 ° C) for a minimum of 1 week. 
Fixed cells were then removed and washed three times 
with 10 volumes of PBS before use in experiments. 
Lipid extraction of formaldehyde-fixed r blood cells with 
chloroform / methanol [10] 
Formaldehyde-fixed cells were washed three times in 
10 volumes of PBS and an additional two times with 10 
volumes of distilled water and one time with 10 volumes 
methanol. The cells were suspended in 7 volumes of 
methanol. 14 volumes of chloroform were added, the tube 
was capped and allowed to sit at 21-24° C for 1 h. The 
cells were then centrifuged and washed twice with 10 
volumes of methanol, twice with 10 volumes of distilled 
water, and twice with PBS before use in experiments. 
Lipid extraction of formaldehyde-fixed r blood cells with 
ethanol [10] 
Formaldehyde-fixed cells were washed as in the previ- 
ous section. The cells were suspended in 10 volumes of 
ethanol and kept at 21-24 °C for 1 h. The cells were 
washed in PBS and prepared for analysis as in the previous 
section. 
2.6. Viscosity determinations of suspending media used in 
electrophoretic mobility measurements 
The viscosities of the various suspending media were 
estimated by means of an Ostwald viscometer immersed in 
a tank thermostated at 25 + 0.2 ° C. 
2.7. Electrophoretic mobility measurements on erythro- 
cytes in various suspending media [10,11] 
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Fig. l. Viscosity-corrected electrophoretic mobilities (/xm/s per V per 
cm) of red blood cells (RBC) from normais and Alzheimer patients at 
different concentrations f dextran T500 (top) and poly(ethylene glycol) 
(PEG) 8000 (bottom). See text for discussion. 
face being discarded. The PEG-rich top and the dextran-rich 
bottom phases were centrifuged at 12000 X g for 15 min 
to ensure that phase separation was complete. Top phase 
was removed leaving all remaining bottom phase and some 
top phase behind in the centrifuge tube. Bottom phase was 
pipetted out of the latter from the middle of the bottom 
phase being careful to keep residual top phase from enter- 
ing the pipette. 
Aliquots of the cell suspensions in PBS (see above) 
were diluted 1:1 (by weight) with top or bottom phase (of 
the phase system indicated in the tables), 4, 8 or 12% 
(w/w)  dextran in PBS or 1, 2, 3, 5, 6 or 8% (w/w)  PEG 
in PBS for EPM measurements (as indicated in Fig. 1). 
Cell microelectrophoresis was carded out in a cylindri- 
cal chamber (Rank Brothers, Cambridge, UK) at 25 + 
0.2 ° C with transillumination [16]. In each sample the rates 
of migration of ten individual RBC were obtained at the 
stationary level for the calculation of EPM in /xm/s per V 
per cm [16]. The rates of migration were observed in 
alternate directions. 
RBC (fresh, enzyme treated, fixed, fixed and lipid-ex- 
tracted) were washed three times with PBS and a suitable 
cell aliquot was, finally, suspended in PBS. 
Phase systems were mixed and permitted to settle in a 
separatory funnel overnight at 21-24 °C. Top and bottom 
phases were then separated with the material at the inter- 
2.8. Presentation of data 
The EPM of the RBC in the different media were 
corrected to the viscosity of water [16]. The EPM obtained 
in the different suspending media are presented, in each 
case, as the mean ___ S.D. with the number of different 
H. Walter, K.E. Widen / Biochimica et Biophysica A cta 1234 (1995) 184-190 187 
individuals in parentheses. Since the S.D. were small in 
experiments with AD and normal untreated blood samples, 
the selection of the smaUer number of samples ubjected to 
the various treatments (Table 1) was arbitrary. P values 
were obtained by one way analysis of variance (ANOVA). 
3. Results and discussion 
3.1. Effect of different suspending media on the relative 
electrophoretic mobilities of RBC from Alzheimer patients 
and normal individuals 
RBC from AD patients and normal individuals have 
EPM that are identical in PBS but differ significantly in 
some polymer solutions (e.g., PEG, bottom phase (from a 
dextran-PEG aqueous phase system)) [7]. The relationship 
between the viscosity-corrected EPM of AD or normal 
RBC and PEG concentration is shown in Fig. 1. 
Despite the differences in EPM between AD and nor- 
mal RBC in PEG or dextran-rich bottom phase (diluted 1:1 
with PBS) (Table 1 and [7]) it is intriguing that no mobility 
difference can be found in dextran solutions (Fig. 1) or in 
diluted PEG-rich top phase [7]. We have suggested [7] that 
this phenomenon may be a consequence of the contami- 
nant(s) (probably originating in dextran) which is visible at 
the interface when dextr~Ln-PEG phase systems are made 
and permitted to phase separate. The interface is discarded 
when the PEG-rich top and dextran-rich bottom phases are 
collected and the bottom phase is thereby depleted of the 
contaminant(s). Particula~tes often partition between the 
interface and the PEG-rich top phase in dextran-PEG 
phase systems [5,6] and it is not unlikely that the contami- 
nant(s) also partitions in this manner. This would explain 
the elimination in PEG-rich top phase of the difference in 
EPM between AD and normal RBC found in PEG solu- 
tions (Fig. 1). 
To probe the above-described hypothesis a number of 
experiments were carried out (data not shown). (1) A 
solution composed of dextran, PEG and salts approximat- 
ing the composition of bottom phase (as used in the tables) 
was made. This 'bottom phase' yielded no difference in 
EPM between AD and normal RBC indicating that phase 
separation is essential to obtain the indicated EPM differ- 
ence. (2) Bottom phase, obtained by phase separation, 
collected either together with the interface or to which 
interracial material (5 -10% by volume) was added did not 
yield a difference in EPM between AD and normal RBC. 
(3) PEG solutions (5% (w/w)  PEG) to which interracial 
material (5-10% by volume) from a dextran-PEG phase 
system had been added also gave no difference in EPM 
between AD and normal RBC. (4) Bottom phase to which 
top phase (5 or 10% by volume) obtained after phase 
system separation had been added, gave no difference 
between AD and normal RBC; while bottom phase to 
which PEG solution (to a concentration of 0.25% or 0.5% 
(w/w)  PEG in addition to that already present in bottom 
phase) was added continued to give a difference in EPM 
between AD and normal RBC. These latter experiments 
show that it is not the high concentration of PEG in (1:1 
diluted) top phase that prevents detection of the indicated 
difference in EPM, but rather something present in the 
phase-separated PEG-rich top phase. All  of these results 
reinforce the conclusion that the interface and the top 
phase contain material which eliminates the EPM differ- 
ence between AD and normal RBC observed in bottom 
phase or PEG solutions. 
3.2. Electrophoretic mobilities of native and chemically 
modified RBC from Alzheimer patients and normal individ- 
uals in phosphate-buffered saline and in bottom phase 
The nature of the surface component(s) responsible for 
the EPM difference in bottom phase between AD and 
normal RBC was probed by treating these RBC in vitro in 
a number of different ways (Table 1) and determining the 
effect of each treatment on their relative EPM. In these 
studies bottom phase rather than PEG solution was chosen 
Table 1 
Viscosity-corrected electrophoretic mobilities aof fresh, enzymatically treated, formaldehyde-fixed, andformaldehyde-fixed, lipid extracted red blood cells 
(RBC) from Alzheimer patients and normal individuals in different suspending media 
Treatment PBS b Bottom phase c
normal RBC Alzheimer RBC normal RBC Alzheimer RBC 
None - 1.08 + 0.01 (18) - 1.08 + 0.01 (18) N.S. -4.56 + 0.05 (18) - 4.87 + 0.07 (18) P < 0.01 
Chymotrypsin -0.91 + 0.01 (8) -0.92 + 0.02 (8) N.S. -3.81 -i- 0.12 (8) -4.14 + 0.09 (8) P < 0.01 
Trypsin - 0.81 + 0.01 (7) - 0.81 -t- 0.02 (7) N.S. - 3.48 + 0.14 (7) - 3.53 + 0.16 (7) N.S. 
Formaldehyde fixed - 1.09 -t- 0.01 (8) - 1.09 + 0.01 (8) N.S. -4.61 + 0.09 (8) -4.88 +_ 0.11 (8) P < 0.01 
Fixed, CHC13/MeOH extracted - 1.08 + 0.01 (8) - 1.08 -1- 0.01 (8) N.S. - 3.97 + 0.08 (8) -4.17 _+ 0.07 (8) P < 0.01 
Fixed, EtOH extracted - 0.96 + 0.02 (8) - 0.95 + 0.02 (8) N.S. - 3.41 + 0.07 (8) - 3.62 + 0.11 (8) P < 0.01 
a Data present the mean electrophoretic mobilities, EPM, (/zm/s per V per cm), + S.D. with the number of experiments in parentheses. 
b Phosphate-buffered saline (PiqS) was composed of 0.15 M NaCI + 0.01 M sodium phosphate buffer, pH 6.8 (NaPB). 
¢ Bottom phase was from a system containing 5% (w/w) dextran (Dx) T500, 3.5% (w/w) poly(ethylene glycol) (PEG) 8000, 0.15 M NaCI and 0.01 M 
NaPB. Bottom phase is Dx-ricll. Bottom phase was diluted 1:1 with the indicated RBC suspension i  PBS followed by measuring cell EPM. 
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Table 2 
Viscosity-corrected electrophoretic mobilities a of young and old red blood cells b (RBC) from Alzheimer patients and normal individuals in different 
suspending media 
Suspending media RBC 
normal young c normal old c Alzheimer young Alzheimer old 
PBS d - -  1.08 + 0.01 (9) -- 1.08 + 0.0l (9) N.S. - 1.08 + 0.01 (6) - 1.08 + 0.01 (6) N.S. 
Dextran e - 3.99 + 0.13 (9) -4.33 + 0.13 (9) P < 0.01 -4.05 + 0.10 (6) -4.41 + 0.13 (6) P < 0.01 
Bottom phase f -4.54 + 0.04 (6) -4.61 + 0.06 (6) P < 0.03 -4.77 + 0.07 (6) -4.87 + 0.10 (6) N.S. 
PEG e - 1.41 + 0.01 (6) - 1.44 + 0.03 (6) P < 0.04 - 1.45 + 0.02 (6) - 1.48 _+ 0.03 (6) P < 0.01 
Top phase f - 1.82 + 0.03 (6) - 1.86 + 0.03 (6) P < 0.04 - 1.83 + 0.03 (6) - 1.86 + 0.03 (6) N.S. 
a Data present the mean electrophoretic mobilities, EPM, ( /zm/s per V per cm), _+ S.D. with the number of experiments in parentheses. 
b Obtained by centrifugal fractionation method. 
c Data of normal young and old red blood cells are taken from Walter and Widen, Biochim. Biophys. Acta. (1994) 1194, 131-137. 
d Phosphate-buffered saline (PBS) was composed of 0.15 M NaCI + 0.01 M sodium phosphate buffer, pH 6.8 (NaPB). 
e EPM were measured in a 4% dextran (Dx) T500 solution in PBS and a 2.5% poly(ethylene glycol) (PEG) 8000 solution in PBS. 
f Top and bottom phases were from a system containing 5% (w/w) Dx T500, 3.5% (w/w) PEG 8000, 0.15 M NaC1 and 0.01 M NaPB. Top phase is 
PEG-rich and bottom phase is Dx-rich. Top and bottom phases were diluted 1:1 with the indicated RBC suspension i PBS followed by measuring cell 
EPM. 
because the EPM dif ference between AD and normal  RBC 
is larger, on a percentage basis, in this suspending med ium 
[7]. 
First note that (Table 1), measured in PBS, the EPM of  
both AD and normal  RBC is the same ( -1 .08  /xm/s  per 
V per cm) [7]. When treated wi th  chymotryps in  these cel ls '  
EPM is reduced by about 16% ( -0 .91  / . tm/s  per V per 
cm) and with trypsin by 25% ( -0 .81  / zm/s  per V per 
cm). Formaldehyde- f ixat ion r formaldehyde- f ixat ion fol- 
lowed by membrane l ipid extract ion with ch lo ro form/  
methanol  causes no change in mobi l i ty  whi le  f ixed cell 
extract ion with ethanol  results in a reduct ion in EPM of  
12% ( -0 .96  / zm/s  per V per cm). 
Measured in bottom phase AD RBC have a h igher 
v iscosity-corrected EPM ( -4 .87  /~m/s  per V per cm) 
than normal  RBC ( -4 .56  / zm/s  per V per cm) [7]. 
Chymotryps in -  or trypsin-treated or formaldehyde- f ixed 
normal  RBC have EPM reduced, respectively,  by 16, 24 
and 1% in relat ion to the untreated normal  RBC.  These 
percentage reduct ions in EPM are comparable  to those 
found for these cells in PBS (see above). F ixat ion of  
normal  RBC w i th  fo rmaldehyde fo l lowed by  
ch lo ro form/methano l  or ethanol  extract ion gives EPM 
that are substantial ly reduced with respect to untreated 
cells (i.e., 13 and 25%, respect ively)  and thus differ f rom 
these cel ls '  e lectrophoret ic  behav ior  in PBS. This  result 
emphas izes  (see also [11]) that e lectrophoret ic  gauging of  
cell surface charge in PBS and of  surface propert ies mani-  
fested by interact ion between cell surface and po lymer  in 
the suspending med ium can differ. AD RBC have a per- 
centage reduct ion in EPM fo l lowing each treatment,  with 
respect to untreated AD RBC,  that mimics  that of  normal  
RBC with the except ion of cells treated with trypsin. 
Tryps in causes a larger reduct ion in EPM of  AD RBC 
( -4 .87  to -3 .53  /xm/s  per  V per cm, 28%)  than of  
normal  RBC ( - 4.56 to - 3.48 / zm/s  per V per cm, 24%) 
thereby e l iminat ing the EPM dif ference between trypsin- 
treated AD and normal  RBC (Table 1). Thus, a di f ference 
Table 3 
Viscosity-corrected electrophoretic mobilities a of young and old red blood cells b (RBC) from Alzheimer patients and normal individuals in different 
suspending media 
Suspending media RBC 
normal young c Alzheimer young normal old c Alzheimer old 
PBS d - -  1.08 + 0.01 (9) -- 1.08 + 0.01 (6) N.S. - 1.08 + 0.0l (9) - 1.08 + 0.01 (6) N.S. 
Dextran c - 3.99 + 0.13 (9) -4.05 + 0.10 (6) N.S. -4.33 __+ 0.13 (9) -4.41 + 0.13 (6) N.S. 
Bottom phase f -4.54+0.04(6)  -4.77+0.07(6)  P< 0.01 -4.61+0.06(6)  -4.87+0.10(6)  P < 0.01 
PEG ¢ - 1.41 + 0.01 (6) - 1.45 + 0.02 (6) P < 0.01 - 1.44 + 0.03 (6) - 1.48 + 0.03 (6) P < 0.03 
Top phase f - 1.82 + 0.03 (6) - 1.83 + 0.03 (6) N.S. - 1.86 -t- 0.03 (6) - 1.86 + 0.03 (6) N.S. 
a Data present the mean electrophoretic mobilities, EPM, ( btm/s per V per cm), + S.D. with the number of experiments in parentheses. 
b Obtained by centrifugal fractionation method. 
c Data of normal young and old red blood cells are taken from Walter and Widen, Biochim. Biophys. Acta. (1994) 1194, 131-137. 
d Phosphate-buffered saline (PBS) was composed of 0.15 M NaCI + 0.01 M sodium phosphate buffer, pH 6.8 (NaPB). 
EPM were measured in a 4% dextran (Dx) T500 solution in PBS and a 2.5% poly(ethylene glycol) (PEG) 8000 solution in PBS. 
f Top and bottom phases were from a system containing 5% (w/w) Dx T500, 3.5% (w/w) PEG 8000, 0.15 M NaC1 and 0.01 M NaPB. Top phase is 
PEG-rich and bottom phase is Dx-rich. Top and bottom phases were diluted 1:1 with the indicated RBC suspension i PBS followed by measuring cell 
EPM. 
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in EPM between AD and normal RBC is retained subse- 
quent o every in vitro treatment to which these cells were 
subjected (Table 1) other lhan trypsin. 
It appears that proteo]ytic modification of the RBC 
surfaces with an appropriate nzyme eliminates the EPM 
difference between AD and normal RBC in bottom phase. 
3.3. Electrophoretic mobiLities of young and old RBC from 
Alzheimer patients and normal individuals in a number of 
different suspending media 
tions the differences between AD and normal RBC and 
between young and old RBC are distinct. The EPM of AD 
and normal RBC differ in bottom phase or PEG but not in 
dextran solution; while the EPM of young and old RBC 
differ predominantly in dextran. 
3.4. Electrophoretic mobilities in phosphate-buffered saline 
and in bottom phase of RBC from Alzheimer patients and 
normal individuals from blood collected in different anti- 
coagulants 
Human normal young and old RBC (obtained by a 
centrifugation method [14]) have, like unfractionated AD 
and normal RBC populations, identical EPM in PBS [8]. 
Unlike AD and normal RBC they display markedly differ- 
ent EPM in solutions of dextran [9]. Much smaller differ- 
ences in EPM, on a percentage basis, are also found for 
both normal and AD patient young and old RBC in PEG 
solution and, for normal young and old RBC, in bottom 
and top phases (see [10] and Table 2). 
The reported increase of IgG on the AD RBC surface 
[3], which mimics the behavior of normal old RBC, has led 
to the suggestion that AD RBC age abnormally [1-3]. We 
therefore compared the EPM of young and old RBC from 
AD patients to each other and to their normal counterparts. 
In Table 2, we show the EPM of AD young and old RBC 
in the five above-indicated suspending media. Again no 
difference in EPM is in evidence in PBS while a clear 
difference between AD young and old RBC is found in 
dextran and a smaller difference also in PEG. It is unlikely 
that the borderline differences, in terms of percentage, 
found between normal young and old RBC in top and 
bottom phases and their absence between AD young and 
old RBC are of importance. However, when normal young 
and AD young RBC or normal old and AD old RBC are 
compared (Table 3) the only differences in EPM observed 
are in bottom phase and in PEG solution, which thus 
duplicate the behavior of the respective unfractionated 
RBC [7]. 
By the criterion of cell electrophoresis in polymer solu- 
Even though RBC are washed repeatedly with PBS 
prior to suspension in the medium selected for EPM 
measurements (see Materials and methods), the manner of 
blood collection (i.e., anticoagulant employed or defibrina- 
tion) is found to markedly influence the results obtained 
with AD and normal RBC. (The difference in EPM be- 
tween young and old RBC obtained in dextran solution is, 
however, irrespective of anticoagulant tested.) 
We examined the effect of a few anticoagulants on the 
relative EPM of AD and normal RBC in bottom phase. 
Table 4 shows that, while the EPM in PBS of these RBC is 
the same irrespective of blood anticoagulant used, only 
collection in citrate or oxalate results in an EPM difference 
between AD and normal RBC in bottom phase. The EPM 
values of AD and of normal RBC, respectively, and the 
EPM differences between AD and normal RBC in these 
two anticoagulants are identical (Table 4). 
RBC from normal and AD patient blood collected in 
heparin, EDTA or by defibrination cannot be differentiated 
in bottom phase. Of these only heparin gives rise to an 
EPM in bottom phase for normal RBC similar to that of 
these cells obtained using citrate or oxalate (Table 4). 
Hence, the higher mobility in bottom phase of AD RBC 
from citrated or oxalated blood would appear to be re- 
duced to that of normal RBC with heparin. On the other 
hand, normal RBC cells have, with respect o RBC in 
blood collected in citrate, oxalate or heparin, elevated 
EPM when it is collected in EDTA or is defibrinated 
(Table 4). In any case, as judged by cell EPM in bottom 
Table 4 
Viscosity-corrected electrophoretic mobilities a of red blood cells (RBC) from Alzheimer or normal blood collected in different anticoagulants or 
defibrinated 
Anticoagulat ion treatment ]?BS b Bottom phase c 
normal RBC Alzheimer RBC normal RBC Alzheimer RBC 
Citrate - 1.08 + 0.01 (8) - 1.08 _+ 0.01 (8) N.S. - 4.50 + 0.07 (8) - 4.85 ___ 0.07 (8) P < 0.01 
Oxalate - 1.09 + 0.01 (5) - 1.09 + 0.01 (5) N.S. - 4.49 + 0.04 (5) - 4.83 + 0.04 (5) P < 0.01 
Heparin - 1.08 + 0.01 (5) - 1.08 _ 0.01 (5) N.S. - 4.53 + 0.06 (5) - 4.56 + 0.08 (5) N.S. 
EDTA - 1.08 + 0.00 (5) - 1.09 5:0.01 (5) N.S. - 4.73 _+ 0.08 (5) - 4.75 _+ 0.11 (5) N.S. 
Defibrination - 1.09 +_ 0.01 (5) - 1.08 _+ 0.01 (5) N.S. - 4.72 _+ 0.08 (5) - 4.75 _+ 0.07 (5) N.S. 
a Data present he mean electrophoretic mobilities, EPM, ( / . tm/s  per V per cm), + S.D. with the number of experiments in parentheses. 
b Phosphate-buffered saline (PBS) was composed of  0.15 M NaC1 + 0.01 M sodium phosphate buffer, pH 6.8 (NaPB). 
c Bottom phase was from a system containing 5% (w/w)  dextran (Dx) T500, 3.5% (w/w)  poly(ethylene glycol) (PEG) 8000, 0.15 M NaC1 and 0.01 M 
NaPB. Bottom phase is Dx-rich. Bottom phase was diluted 1:1 with the indicated RBC suspension in PBS fol lowed by measuring cell EPM. 
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phase, the surface of normal RBC from blood collected in 
EDTA (or defibrinated) iffers from that of RBC collected 
in the other three anticoagulants. 
Currently, one can only conjecture as to the basis for 
the differential anticoagulant effects on the relative EPM 
of RBC from AD patients and normals. Disturbances in 
calcium homeostasis n AD have been reported [17,18] as 
reflected in increased calcium levels and decreased levels 
of calcium-binding proteins in AD brain tissue [17]. Cal- 
cium abnormalities have also been found in blood plasma 
in AD [4]. Possibly citrate or oxalate which bind calcium, 
thus preventing blood from clotting, reflect aspects of 
these differences. In contrast, heparin inactivates thrombin 
in the presence of serum and thus acts in a part of the 
clotting cascade unrelated to calcium. Heparin also binds 
many proteins (e.g., fl-amyloid protein [19]) and such 
binding may be related to the absence of the above-indi- 
cated relative difference in EPM. The action of EDTA, 
which prevents clotting by removing calcium, is more 
wide-ranging than that of either citrate or oxalate. Its 
reactivities include chelation of metals, some of which are 
reported to differ [20] or be involved in modulatory effects 
[21] in AD, and inhibition of metal-requiring proteinases. 
Defibrination involves the physical removal of the (pre- 
dominantly) fibrin clot as it forms and thus also gives rise 
to a cell environment distinct from those obtained with the 
above anticoagulants. 
Since the difference in EPM between AD and normal 
RBC appears to be protein-dependent a d anticoagulant- 
related, it may involve an anticoagulant-associated interac- 
tion between the respective cells and their compositionally 
differing [4] plasma proteins. Such interaction would have 
to take place before or at the time blood is collected in 
anticoagulant because when AD and normal RBC (blood- 
group matched) are incubated in each other's plasma or 
serum the EPM of the cells and, hence, the EPM differ- 
ence between them, is unaffected (data not shown). 
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